641 related articles for article (PubMed ID: 27543504)
1. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
[TBL] [Abstract][Full Text] [Related]
2. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
Lightner AL; Mathis KL; Tse CS; Pemberton JH; Shen B; Kochhar G; Singh A; Dulai PS; Eisenstein S; Sandborn WJ; Parry L; Stringfield S; Hudesman D; Remzi F; Loftus EV
Inflamm Bowel Dis; 2018 Mar; 24(4):871-876. PubMed ID: 29509927
[TBL] [Abstract][Full Text] [Related]
3. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations.
Lightner AL; McKenna NP; Tse CS; Raffals LE; Loftus EV; Mathis KL
Aliment Pharmacol Ther; 2018 Mar; 47(5):573-580. PubMed ID: 29250800
[TBL] [Abstract][Full Text] [Related]
4. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
Lightner AL; Tse CS; Potter DD; Moir C
J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
[TBL] [Abstract][Full Text] [Related]
5. Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis.
Lightner AL; McKenna NP; Moncrief S; Pemberton JH; Raffals LE; Mathis KL
Inflamm Bowel Dis; 2017 Dec; 23(12):2197-2201. PubMed ID: 28858072
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
[TBL] [Abstract][Full Text] [Related]
7. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab.
Yamada A; Komaki Y; Patel N; Komaki F; Aelvoet AS; Tran AL; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
Am J Gastroenterol; 2017 Sep; 112(9):1423-1429. PubMed ID: 28719595
[TBL] [Abstract][Full Text] [Related]
8. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
9. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
10. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A
J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898
[TBL] [Abstract][Full Text] [Related]
11. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
[TBL] [Abstract][Full Text] [Related]
12. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
14. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
16. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
[TBL] [Abstract][Full Text] [Related]
17. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
Eriksson C; Marsal J; Bergemalm D; Vigren L; Björk J; Eberhardson M; Karling P; Söderman C; ; Myrelid P; Cao Y; Sjöberg D; Thörn M; Karlén P; Hertervig E; Strid H; Ludvigsson JF; Almer S; Halfvarson J
Scand J Gastroenterol; 2017; 52(6-7):722-729. PubMed ID: 28362144
[TBL] [Abstract][Full Text] [Related]
18. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study.
Kim JY; Zaghiyan K; Lightner A; Fleshner P
BMC Surg; 2020 Mar; 20(1):46. PubMed ID: 32138717
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor.
Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X
Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098
[TBL] [Abstract][Full Text] [Related]
20. Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics.
Novello M; Stocchi L; Steele SR; Holubar SD; Duraes LC; Kessler H; Shawki S; Hull LT
J Crohns Colitis; 2020 Feb; 14(2):185-191. PubMed ID: 31328222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
